Table S1: PCR primers for sequencing of ATG-site morpholino target region

Gene	Target Sequence
pnpla3	5' CCGCAGCTGTATCCCTTCTA 3', 5' GCATTACCTATGCAAGCCTCT 3'
cpn1	5' CAGCAATCATGCCTCAAAAA 3', 5' GCCCTCACCATCTCCTCATA 3'
trib1	5' TTGCGTGAAATCAGACGGTA 3', 5' ACTCTCAGCCAGGAAGGACA 3'
fads2	5' TTTGCTTTTGTGACCCAGTG 3', 5' GCACCAAGCCAATGTTTCTA 3'
mif	5' GCGGGGTTTTACGGTAGTCT 3', 5' GTGCTTACAGTTTTCTATCCCATCT 3'
slc2a2	5' AAGGTCTGATCCCAGCACAC 3', 5' CTCCGGTCAATTTTGCAGTT 3'
pklr	5' AGCTTCAGGGAAGATGAGCA 3', 5' TTTGGGAGAGGGATGATTTG 3' and 5' TGCCTGAAGTCTTTTCTCTTATTTT 3', 5' TCCAGCAGACACAGATGCTC 3'
mapk10	5' TGCCTTGTTGAGCGTAGTTG 3', 5' CTAAGGAGGGGTTTGGGAAC 3' and 5' CCTTCACGAACACCATCAGA 3', 5' CTCACAGAATGGAAGTGAATGAA 3'
aldob	5' ATCGTTCAGTCCCGATTCAC 3', 5' CACTTGCATGTTCACGGTTC 3'
efna1a	5' CGCGGATCTCTTGATTCAGT 3', 5' CGAACACAGCGCAGATACTC 3'
efna1b	5' GCATTTAACCGCGTCTGTTT 3', 5' CGCACACAGCTTGCATTAAG 3'
samm50	5' CAACGTGACGTGGTTGTTCT 3', 5' GTTTCTGAACTCGGCCTGTC 3'
mical3a	5' TCATTCAGGGTGAAAATGTCC 3', 5' AAGCCTTGAGAGTGCCTTTG 3'
mical3b	5' ATTGTCTGCTCCCCATTCAG 3', 5' TTTCTGGCAGGCTCTTTTGT 3'

Table S2: Effect of gene knockdown using splice site morpholinos on hepatic progenitor population (*hhex* expression).

Morpholino	% small	% normal	% large	n	Significance
control	21.2%	73.7%	5.1%	99	
pnpla3	43.8%	56.3%	0.0%	112	$p < 0.05$
control	18.1%	71.4%	10.5%	105	
cpn1	19.0%	71.4%	9.5%	84	n.s.
control	14.3%	80.0%	5.7%	35	
trib	25.0%	65.0%	10.0%	40	n.s.
control	10.2%	81.6%	8.2%	49	
fads2	16.0%	76.0%	8.0%	50	n.s.
control	21.2%	61.5%	17.3%	52	
mif	24.1%	70.4%	5.6%	54	n.s.
control	16.7%	72.9%	10.4%	48	.
slc2a3	15.1%	77.4%	7.5%	53	n.s
control	24.6%	69.2%	6.2%	65	
pklr	43.4%	55.8%	0.9%	113	$p < 0.05$
control	12.3%	80.7%	7.0%	57	
mapk10	34.7%	61.3%	4.0%	75	$p < 0.05$
control	19.2%	73.1%	7.7%	78	
aldob	29.5%	65.3%	5.3%	95	n.s.
control	38.1%	61.9%	0.0%	21	
efna1a	48.1%	51.9%	0.0%	27	n.s.
control	23.9%	71.7%	4.3%	46	
efna1b	32.1%	66.1%	1.8%	56	n.s.
control	15.2%	74.2%	10.6%	66	
samm50	15.9%	76.2%	7.9%	63	n.s.
control	18.5%	79.6%	1.9%	54	
mical3a	22.4%	74.1%	0.0%	58	n.s.
control	25.0%	67.6%	7.4%	68	
mical3b	25.3%	65.9%	8.8%	91	n.s.

Table S3: Effect of gene knockdown using splice-site morpholinos on hepatocyte gene expression and liver size (*fabp10a* expression).

Morpholino	% small	% normal	% large	n	Significance
control	23.5%	70.6%	5.9%	34	
pnpla3	71.1%	26.3%	2.6%	38	$p < 0.05$
control	35.6%	53.3%	11.1%	45	
cpn1	78.7%	21.3%	0.0%	47	$p < 0.05$
control	36.4%	63.6%	0%	44	
trib	69.8%	30.2%	0%	53	$p < 0.05$
control	18.2%	74.0%	7.8%	77	
fads2	43.7%	53.5%	2.8%	71	$p < 0.05$
control	40.4%	51.1%	8.5%	47	
mif	31.0%	59.5%	9.5%	42	n.s.
control	23.0%	67.0%	10.0%	100	
slc2a3	54.7%	35.9%	9.4%	117	$p < 0.05$
control	26.2%	59.0%	14.8%	61	
pklr	67.2%	29.5%	3.3%	61	$p < 0.05$
control	26.9%	73.1%	0.0%	26	
mapk10	87.5%	12.5%	0.0%	48	$p < 0.05$
control	18.0%	72.1%	9.8%	61	
aldob	26.3%	63.2%	10.5%	57	n.s.
control	20.0%	75.0%	5.0%	40	
efna1a	26.8%	68.3%	4.9%	41	n.s.
control	30.4%	60.7%	8.9%	56	
efna1b	32.0%	60.0%	8.0%	50	n.s.
control	8.6%	80.0%	11.4%	35	
samm50	65.4%	34.6%	0.0%	26	$p < 0.05$
control	40.9%	54.5%	4.5%	44	
mical3a	42.9%	50.0%	7.1%	42	n.s.
control	24.4%	63.3%	12.2%	90	
mical3b	32.6%	61.1%	6.3%	95	n.s.

Table S4: Susceptibility to metabolic and toxic injury after gene knockdown using splice-site morpholinos

Gene knockdown	+2% EtOH (Oil Red O)	+2.5 mM APAP (*fabp10a* expression)
pnpla3	unchanged	**reduced**
cpn1	unchanged	unchanged
trib1	unchanged	**reduced**
fads2	unchanged	unchanged
mif	unchanged	unchanged
slc2a2	unchanged	unchanged
pklr	unchanged	unchanged
mapk10	unchanged	unchanged
aldob	unchanged	unchanged
efna1a	unchanged	unchanged
efna1b	unchanged	unchanged
samm50	unchanged	Trend toward **reduced**
mical3a	unchanged	unchanged
mical3b	unchanged	unchanged